[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565155":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":47,"locations":57,"responsibleParty":196,"collaborators":34,"id":198,"slug":199,"hasResults":200,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":34,"eligibilityCriteria":204,"healthyVolunteers":200,"sex":205,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":34,"studyType":211,"phases":212,"briefSummary":215,"conditions":216,"keywords":34,"overallStatus":59,"whyStopped":34,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":228},{"fullName":5,"class":6},"HepaRegeniX GmbH","INDUSTRY",[8,14,18,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Active treatment minor hepatic resection","EXPERIMENTAL","Pilot 1: 5 participants will receive HRX215 starting within 1-3 days after minor liver resection for colorectal liver metastases.",[13],"Drug: HRX215 capsules",{"label":15,"type":10,"description":16,"interventionNames":17},"Active treatment major hepatic resection","Pilot 2: 10 participants will receive HRX215 starting treatment prior to major liver resection for colorectal liver metastases.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Major hepatic resection (Randomized part control arm)","PLACEBO_COMPARATOR","32 participants will receive placebo starting administration prior to major liver resection for colorectal liver metastases",[23],"Drug: Placebo capsules",{"label":25,"type":10,"description":26,"interventionNames":27},"Major hepatic resection (Randomized part)","32 participants will receive HRX215 starting administration prior to major liver resection for colorectal liver metastases.",[13],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","HRX215 capsules","HRX215 250 mg orally twice daily for a total treatment duration of 28 days",[15,9,25],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Placebo capsules","placebo matching appearance of HRX215, orally twice daily for a total treatment duration of 28 days",[19],[40,43],{"name":41,"affiliation":5,"role":42},"Linda E Greenbaum, MD","STUDY_DIRECTOR",{"name":44,"affiliation":45,"role":46},"Patrick Starlinger, MD, PhD","Mayo Clinic","PRINCIPAL_INVESTIGATOR",[48,53],{"name":49,"role":50,"phone":51,"phoneExt":34,"email":52},"Wolfgang Albrecht, PhD NC","CONTACT","+49 7071 7912809","info@heparegenix.com",{"name":54,"role":50,"phone":55,"phoneExt":34,"email":56},"Linda Greenbaum, MD","484-343-2409","l.greenbaum@heparegenix.com",[58,74,90,107,120,135,152,166,180],{"facility":45,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-92.4699,44.02163,{"lat":69,"lon":68},[72],{"name":73,"role":46,"phone":34,"phoneExt":34,"email":34},"Patrick Starlinger, M.D Ph.D.",{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":63,"countryCode":64,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Cleveland Clinic","NOT_YET_RECRUITING","Cleveland","Ohio","44195",{"type":66,"coordinates":81},[82,83],-81.69541,41.4995,{"lat":83,"lon":82},[86],{"name":87,"role":50,"phone":88,"phoneExt":34,"email":89},"Frederico Aucejo, MD","216-444-0537","aucejof@ccf.org",{"facility":91,"status":59,"city":92,"state":34,"zip":34,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Centre Hospitalier Régional Universitaire de Lille (CHRU) Hôpital Claude Huriez","Lille","France","FR",{"type":66,"coordinates":96},[97,98],3.05512,50.63391,{"lat":98,"lon":97},[101,105],{"name":102,"role":50,"phone":103,"phoneExt":34,"email":104},"Stephanie Truant, MD. PhD","+33 3-2044-4260","Stephanie.TRUANT@chu-lille.fr",{"name":106,"role":46,"phone":34,"phoneExt":34,"email":34},"Stephanie Truant, MD, PhD",{"facility":108,"status":59,"city":109,"state":34,"zip":34,"country":93,"countryCode":94,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Hôpital Paul-Brousse - Centre Hepato-Biliaire (CHB)","Villejuif",{"type":66,"coordinates":111},[112,113],2.35992,48.7939,{"lat":113,"lon":112},[116],{"name":117,"role":50,"phone":118,"phoneExt":34,"email":119},"René Adam, MD, PhD","+33 1 45 59 30 49","rene.adam@pbr.aphp.fr",{"facility":121,"status":59,"city":122,"state":34,"zip":34,"country":123,"countryCode":124,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Univ. Tuebingen - Universitaetsklinik fuer Allgemeine, Viszeral- und Transplantationschirurgie","Tübingen","Germany","DE",{"type":66,"coordinates":126},[127,128],9.05222,48.52266,{"lat":128,"lon":127},[131],{"name":132,"role":50,"phone":133,"phoneExt":34,"email":134},"Silvio Nadalin, MD. PhD","+49 7071-29-83387","silvio.nadalin@med.uni-tuebingen.de",{"facility":136,"status":59,"city":137,"state":34,"zip":34,"country":138,"countryCode":139,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Rabin Medical Center","Petah Tikva","Israel","IL",{"type":66,"coordinates":141},[142,143],34.88747,32.08707,{"lat":143,"lon":142},[146,150],{"name":147,"role":50,"phone":148,"phoneExt":34,"email":149},"Eran Sadot, MD, PhD, Professor","+972 54 2222021","EranSa3@clalit.org.il",{"name":151,"role":46,"phone":34,"phoneExt":34,"email":34},"Eran Sadot, M, PhD, Professor",{"facility":153,"status":59,"city":154,"state":34,"zip":34,"country":138,"countryCode":139,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Sheba Medical Center","Ramat Gan",{"type":66,"coordinates":156},[157,158],34.81065,32.08227,{"lat":158,"lon":157},[161,165],{"name":162,"role":50,"phone":163,"phoneExt":34,"email":164},"Niv Pencovich, MD, PhD, Professor","+972 52 7360036","Niv.Pencovich@sheba.health.gov.il",{"name":162,"role":46,"phone":34,"phoneExt":34,"email":34},{"facility":167,"status":59,"city":168,"state":34,"zip":34,"country":138,"countryCode":139,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Tel-Aviv Sourasky MC","Tel Aviv",{"type":66,"coordinates":170},[171,172],34.78057,32.08088,{"lat":172,"lon":171},[175,179],{"name":176,"role":50,"phone":177,"phoneExt":34,"email":178},"Nir Lubezky, MD, PhD, Professor","+972 52 7360056","nirl@tlvmc.gov.il",{"name":176,"role":46,"phone":34,"phoneExt":34,"email":34},{"facility":181,"status":76,"city":182,"state":34,"zip":34,"country":183,"countryCode":184,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"South Texas Accelerated Research Therapeutics Madrid - CIOCC - Universitario Sanchinarro","Madrid","Spain","ES",{"type":66,"coordinates":186},[187,188],-3.70256,40.4165,{"lat":188,"lon":187},[191,195],{"name":192,"role":50,"phone":193,"phoneExt":34,"email":194},"Riccardo Caruso, MD, PhD","+34 917 56 78 00","ricaruso2@gmail.com",{"name":192,"role":46,"phone":34,"phoneExt":34,"email":34},{"type":197,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100565155","phase-1-safety-of-hrx215-in-patients-after-minor-and-major-liver-resection-100565155",false,"NCT06638502","Safety of HRX215 in Patients After Minor and Major Liver Resection","Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of HRX215 in Participants After Major Hepatectomy, Preceded by Two Open Pilot Parts in Participants After Minor and After Major Hepatectomy Due to Colon Carcinoma Metastases","Inclusion Criteria:\n\n* Participants with liver metastases originating from colon carcinoma planned for R0-intended hepatectomy for colorectal liver metastases\n* Part 1 only: stable participants within 1-3 days after minor liver resection, normal non-tumor liver parenchyma\n* Part 2 and 3 only: Major liver resection.\n* Low estimated risk for post-hepatectomy liver failure PHLF\n\nFurther inclusion criteria apply\n\nExclusion Criteria:\n\n* Liver Cirrhosis\n* Preoperative presence of clinical ascites\n* Any other hepatobiliary cancer\n* BMI \\>35 kg\u002Fm2\n* ASA Score \\>4\n* Peritoneal carcinomatosis\n\nFurther exclusion criteria apply","ALL","18 Years","75 Years",{"count":209,"type":210},80,"ESTIMATED","INTERVENTIONAL",[213,214],"PHASE1","PHASE2","The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases.\n\nThe objectives are:\n\n1. to learn about the safety and tolerability of HRX215\n2. to learn about how the body absorbs, distributes, and gets rid of HRX215.\n3. to learn about clinical activity of HRX215\n\nResearchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.",[217,218],"Liver Resection","Colorectal Carcinoma Liver Metastases","2026-06-30",{"date":221,"type":222},"2026-07-01","ACTUAL",{"date":224,"type":222},"2025-05-06",{"date":226,"type":210},"2027-12-31",{"name":5,"class":6},9]